Analyzing Oruka Therapeutics (NASDAQ:ORKA) and OncoCyte (NASDAQ:OCX)

OncoCyte (NASDAQ:OCX) and Oruka Therapeutics (NASDAQ:ORKA) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, dividends, institutional ownership, risk, profitability, analyst recommendations and valuation.

Analyst Recommendations

This is a summary of current recommendations and price targets for OncoCyte and Oruka Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OncoCyte	0	1	2	0	2.67
Oruka Therapeutics	0	0	6	2	3.25

OncoCyte currently has a consensus price target of $4.42, indicating a potential upside of 69.22%. Oruka Therapeutics has a consensus price target of $43.17, indicating a potential upside of 79.56%. Given Oruka Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Oruka Therapeutics is more favorable than OncoCyte.

Earnings and Valuation

This table compares OncoCyte and Oruka Therapeutics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OncoCyte	$1.50 million	29.28	-$27.78 million	N/A	N/A
Oruka Therapeutics	N/A	N/A	-$5.34 million	($6.26)	-3.84

Oruka Therapeutics has lower revenue, but higher earnings than OncoCyte.

Profitability

This table compares OncoCyte and Oruka Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
OncoCyte	-6,122.29%	-269.32%	-59.71%
Oruka Therapeutics	N/A	-24.96%	-21.22%

Risk & Volatility

OncoCyte has a beta of 1, suggesting that its share price has a similar volatility profile to the S&P 500.Comparatively, Oruka Therapeutics has a beta of 0.87, suggesting that its share price is 13% less volatile than the S&P 500.

Insider & Institutional Ownership

55.4% of OncoCyte shares are owned by institutional investors. Comparatively, 56.4% of Oruka Therapeutics shares are owned by institutional investors. 1.6% of OncoCyte shares are owned by insiders. Comparatively, 22.7% of Oruka Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Oruka Therapeutics beats OncoCyte on 10 of the 12 factors compared between the two stocks.

About OncoCyte

OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test. It also provides testing services for biomarker discovery, assay design and development, clinical trial support, and various biomarker tests. The company has a collaboration agreement with Bio-Rad Laboratories, Inc. (Bio-Rad) to collaborate in the development and the commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad's ddPCR instruments and reagents. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.

About Oruka Therapeutics

ARCA biopharma, Inc., a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company’s cardiovascular science, ARCA’s management team has significant experience in developing and commercializing cardiovascular products. The Company’s business focus combines expertise in cardiovascular pathophysiology, molecular genetics, clinical development and product commercialization. It is currently developing Gencaro (bucindolol hydrochloride), a cardiovascular drug for the treatment of chronic heart failure. The company is based in Broomfield, Colorado.